Recent work in EGFR‐mutant lung cancer revealed that amplification of the CCNE1 gene can be found in patients with acquired resistance to EGFR inhibitors (Blakely et al, 2017) and specifically with acquired resistance to osimertinib (Yang et al, 2018). The gene discussed is EGFR; the disease is lung cancer.